TrialCancer immunology, immunotherapy : CII2026
Neoadjuvant combined immunotherapy with intratumoral TransCon TLR7/8 Agonist and systemic TransCon IL-2 β/y or pembrolizumab in patients with locally advanced oral cancer-a monocentric experience.
Manuel Weber et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.